Steve Pattison
Founder & CEO
Objective Biotechnology
Objective Biotechnology develops integrated neurotechnology tools for in‑vivo brain research, including a lightweight, head‑mounted mini‑mScope and transparent See‑Shell cranial windows that enable cortex‑wide optical access in freely moving rodents. The company also offers an automated microinjection platform (Autoinjector) for high‑throughput genetic manipulation, providing a streamlined workflow from embryo engineering to chronic imaging.
- Artificial Intelligence
- Biotechnology
- Hardware
Updated 5 months ago
Funding
Raised to date
$715KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Am ...?... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...
...
James Grabau
Co‑Founder & CTO
Product
Problem
Neuroscience research on freely moving rodents is limited by bulky imaging equipment, invasive cranial windows, and low-throughput genetic manipulation methods, which constrain the scale and ecological validity of brain‑behavior studies.
Solution
Objective Biotechnology provides an integrated suite of neurotechnology tools that enable cortex‑wide optical access and high‑resolution neural recordings in unrestrained rodents. Their mini‑mScope offers a lightweight, wide‑field imaging microscope that can be mounted on the animal’s head, while the See‑Shell transparent polymer cranial window delivers chronic, minimally invasive optical access. The MagKine Docking System allows rapid, repeatable attachment of imaging devices without anesthesia, and the Robo‑Comm platform automates data acquisition and device control. Complementing these hardware solutions, the company’s fully automated microinjection (Autoinjector) system performs high‑throughput genetic manipulation of embryos, facilitating large‑scale creation of transgenic models. Together, these technologies streamline the workflow from genetic engineering to in‑vivo imaging, expanding experimental throughput and ecological relevance.
Target Audience
Primary customers are academic neuroscience laboratories and biotech research groups that conduct in‑vivo brain imaging and require high‑throughput genetic manipulation in rodent models.
Features
- Mini‑mScope: miniaturized wide‑field fluorescence microscope with sub‑second frame rates for head‑mounted imaging in freely moving rodents
- See‑Shell: transparent polymer cranial window implant providing chronic, large‑area optical access with reduced inflammation compared to glass windows
- MagKine Docking System: magnetic docking platform enabling rapid, repeatable attachment and alignment of imaging devices without repeated surgeries
- Robo‑Comm: integrated hardware‑software communication suite for automated control of imaging parameters, synchronization with behavioral rigs, and real‑time data streaming
- Autoinjector: fully automated microinjection platform capable of high‑throughput embryo injection for precise genetic manipulation across multiple species
- Scalable workflow: seamless transition from embryo microinjection to chronic cranial window implantation and head‑mounted imaging within a single research pipeline